In the Margins
In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.
Most Read
The Investment Company Institute this week made public a set of recommendations to reform and modernize the Investment Company Act of 1940, which has not been ...
Securities brokerage firms are a critical part of the financial landscape, as they provide a vast array of products and services to the financial services industry, ...
The percentage of female independent directors serving on mutual fund boards has increased impressively in recent years, jumping from about 20% 10 years ago to nearly 40% ...
As mutual fund boards prepare for their next quarterly meetings over the coming weeks, they likely are gathering talking points on several of President Trump's initiatives ...